{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:11:25Z","timestamp":1782252685262,"version":"3.54.5"},"reference-count":28,"publisher":"BMJ","issue":"6629","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ"],"published-print":{"date-parts":[[1988,4,16]]},"DOI":"10.1136\/bmj.296.6629.1083","type":"journal-article","created":{"date-parts":[[2009,4,2]],"date-time":"2009-04-02T19:19:55Z","timestamp":1238699995000},"page":"1083-1086","source":"Crossref","is-referenced-by-count":71,"title":["Natural course of penicillamine nephropathy: a long term study of 33 patients"],"prefix":"10.1136","volume":"296","author":[{"given":"C L","family":"Hall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Jawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P R","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J C","family":"MacKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P A","family":"Bacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P T","family":"Klouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A G","family":"MacIver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","reference":[{"key":"ref_1","first-page":"246","article-title":"Gold and D-penicillamine induced renal glomerular disease","volume-title":"The kidney in rheumatic disease","author":"Hail, C.L.","year":"1982","unstructured":"Hail CL. Gold and D-penicillamine induced renal glomerular disease. In: Bacon PA, Hadler NM, eds. The kidney in rheumatic disease. London: Butterworths, 1982:246-66."},{"key":"ref_2","first-page":"180","article-title":"Penicillamine in rheumatoid disease, a long term study","volume":"i:","author":"Day, A.T.; Golding, T.R.; Lee, P.N.; Butterworth, A.D.","year":"1974","unstructured":"Day AT, Golding TR, Lee PN, Butterworth AD. Penicillamine in rheumatoid disease, a long term study. BrMedJ 1974;i:180-3.","journal-title":"BrMedJ"},{"key":"ref_3","first-page":"631","article-title":"Treatment of rheumatoid arthritis with penicillamine","volume":"6","author":"Hill, H.F.H.","year":"1977","unstructured":"Hill HFH. Treatment of rheumatoid arthritis with penicillamine. Semnin Arthritis Rheum 1977;6:631-88.","journal-title":"Semnin Arthritis Rheum"},{"key":"ref_4","first-page":"661","article-title":"Penicillamine nephropathy in rheumatoid arthritis","volume":"45","author":"Bacon, P.A.; Tribe, C.R.; MacKenzie, J.C.; Verrier-Jones, J.; Cumming, R.H.; Amer, B.","year":"1976","unstructured":"Bacon PA, Tribe CR, MacKenzie JC, Verrier-Jones J, Cumming RH, Amer B. Penicillamine nephropathy in rheumatoid arthritis. QJ7 Med 1976;45:661-84."},{"key":"ref_5","first-page":"145","article-title":"Immunopathology of penicillamine induced glomerular disease","volume":"3","author":"Dische, F.E.; Swinson, D.R.; Hamilton, E.B.D.; Parson, V.","year":"1976","unstructured":"Dische FE, Swinson DR, Hamilton EBD, Parson V. Immunopathology of penicillamine induced glomerular disease. 7 Rheumatol 1976;3:145-54.","journal-title":"7 Rheumatol"},{"issue":"3","key":"ref_6","first-page":"109","article-title":"Effect of penicillamine on the kidney","volume":"70","author":"Davison, A.M.; Day, A.T.; Golding, JR, Thomson; D.","year":"1977","unstructured":"Davison AM, Day AT, Golding JR, Thomson D. Effect of penicillamine on the kidney. Proceedings of the Royal Society ofMedicine 1977;70(suppl 3):109-13.","journal-title":"Proceedings of the Royal Society ofMedicine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/ard.38.4.344","article-title":"D-Penicillamine and immune complex deposition","volume":"38","author":"Kirby, J.D.; Dieppe, P.A.; Huskisson, E.C.; Smith, B.","year":"1979","unstructured":"Kirby JD, Dieppe PA, Huskisson EC, Smith B. D-Penicillamine and immune complex deposition. Ann Rheum Dis 1979;38:344-6.","journal-title":"Ann Rheum Dis"},{"key":"ref_8","first-page":"1201","article-title":"Penicillamine induced membranous glomerulonephritis","volume":"i:","author":"Nield, G.H.; Gartner, H.V.; Bohle, A.","year":"1975","unstructured":"Nield GH, Gartner HV, Bohle A. Penicillamine induced membranous glomerulonephritis. Lancet 1975;i: 1201-2.","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000181984","article-title":"Penicillamine nephropathy","volume":"26","author":"Ross, J.H.; McGinty, F.; Brewer, D.G.","year":"1980","unstructured":"Ross JH, McGinty F, Brewer DG. Penicillamine nephropathy. Nephron 1980;26:184-6.","journal-title":"Nephron"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1056\/NEJM198008073030602","article-title":"HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis","volume":"303","author":"Wooley, P.A.; Griffin, T.; Panayi, G.S.; Batchelor, JR, Welsh; KT, GIbson; T.J.","year":"1980","unstructured":"Wooley PA, Griffin T, Panayi GS, Batchelor JR, Welsh KT, GIbson TJ. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N EnglJ Med 1980;303:300-2.","journal-title":"N EnglJ Med"},{"key":"ref_11","first-page":"448","article-title":"HLA-DR antigens and proteinuria induced by aurothioglucose and D-penicillamine in patients with rheumatoid arthritis","volume":"10","author":"Speerstra, R.; Reekers, P.; vam der Putte, L.B.; van den Brouche, JR, RaskerJJ; de Rooi, D.J.","year":"1983","unstructured":"Speerstra R, Reekers P, vam der Putte LB, van den Brouche JR, RaskerJJ, de Rooi DJ. HLA-DR antigens and proteinuria induced by aurothioglucose and D-penicillamine in patients with rheumatoid arthritis. J7 Rheumatol 1983;10:448-53."},{"key":"ref_12","first-page":"156","article-title":"Renal disease and penicillamine","volume":"3","author":"Huskisson, E.C.","year":"1979","unstructured":"Huskisson EC. Renal disease and penicillamine. EurJ Rheumatollnflamm 1979;3:156-9.","journal-title":"EurJ Rheumatollnflamm"},{"issue":"3","key":"ref_13","first-page":"131","article-title":"Rheumatoid arthritis treated with small doses of penicillamine","volume":"70","author":"Golding, JR, Day; AT, Tomkinson; MR, Brown; RM, Hassan; MV, SR, Longstaff","year":"1977","unstructured":"Golding JR, Day AT, Tomkinson MR, Brown RM, Hassan MV, Longstaff SR. Rheumatoid arthritis treated with small doses of penicillamine. Proceedings of the Royal Society ofMedicine 1977;70(suppl 3):131-5.","journal-title":"Proceedings of the Royal Society ofMedicine"},{"key":"ref_14","first-page":"429","article-title":"Maintenance dose of penicillamine in rheumatoid arthritis: a comparison between standard and response related flexible regime","volume":"38","author":"Hill, H.F.H.; Hill, A.G.S.; Day, A.T.; Brown, R.M.; Golding, JR, Lyle; W.H.","year":"1979","unstructured":"Hill HFH, Hill AGS, Day AT, Brown RM, Golding JR, Lyle WH. Maintenance dose of penicillamine in rheumatoid arthritis: a comparison between standard and response related flexible regime. AnnRheumDis 1979;38:429-33.","journal-title":"AnnRheumDis"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.7326\/0003-4819-84-1-100_1","article-title":"Goodpasture's syndrome and D-penicillamine","volume":"84","author":"Gibson, T.; Barry, H.C.; Ogg, C.","year":"1976","unstructured":"Gibson T, Barry HC, Ogg C. Goodpasture's syndrome and D-penicillamine. Ann Intern Med 1976;84: 100-1.","journal-title":"Ann Intern Med"},{"key":"ref_16","first-page":"268","article-title":"Penicillamine induced Goodpasture's syndrome","volume-title":"in rheumatoid disease","author":"McCormack, J.N.; Wood, P.; Bell, D.","year":"1977","unstructured":"McCormack JN, Wood P, Bell D. Penicillamine induced Goodpasture's syndrome. In: Munthe E, ed. Penicillamine in rheumatoid disease. Oslo: Fabritius and S0nner, 1977:268-78."},{"issue":"3","key":"ref_17","first-page":"24","article-title":"The management of cystinuria","volume":"70","author":"Stephens, A.D.","year":"1977","unstructured":"Stephens AD. The management of cystinuria. Proceedings of the Royal Society of Medicine 1977;70(suppl 3):24-6.","journal-title":"Proceedings of the Royal Society of Medicine"},{"key":"ref_18","first-page":"319","article-title":"Membranous nephropathy in patients with rheumatoid arthritis:relationship to gold therapy","volume":"57","author":"Samuels, B.; Lee, J.C.; Engelman, E.P.; Hopper, J.","year":"1977","unstructured":"Samuels B, Lee JC, Engelman EP, Hopper J. Membranous nephropathy in patients with rheumatoid arthritis:relationship to gold therapy. Medicine 1977;57:319-27.","journal-title":"Medicine"},{"key":"ref_19","first-page":"87","article-title":"Membranous glomerulonephritis in rheumatoid arthritis not related to gold or D-penicillamine therapy","volume":"27","author":"Honkanen, E.; Tomroth, T.; Petterson, E.; Skrifrars, B.","year":"1987","unstructured":"Honkanen E, Tomroth T, Petterson E, Skrifrars B. Membranous glomerulonephritis in rheumatoid arthritis not related to gold or D-penicillamine therapy. Clin Nephrol 1987;27:87-93.","journal-title":"Clin Nephrol"},{"key":"ref_20","first-page":"28","article-title":"Penicillamine in rheumatoid arthritis: clinical, pharmacological and biochemical properties. Scand7 Rheumatol","volume":"8","author":"Jaffe, I.A.","year":"1979","unstructured":"Jaffe IA. Penicillamine in rheumatoid arthritis: clinical, pharmacological and biochemical properties. Scand7 Rheumatol 1979;8(suppl 28):58-64."},{"key":"ref_21","article-title":"Accepted 15","year":"1987","unstructured":"(Accepted 15 December 1987)"},{"key":"ref_22","article-title":"Nifedipine was approved for marketing in New Zealand in October 1980 and placed in the Intensive Medicines Monitoring National Toxicology Group, Medical School, PO Box 913","unstructured":"Nifedipine was approved for marketing in New Zealand in October 1980 and placed in the Intensive Medicines Monitoring National Toxicology Group, Medical School, PO Box 913, Dunedin, New Zealand"},{"key":"ref_23","article-title":"After the first two years ofmonitoring ofnifedipine five records of eye problems had been received, three of painful eyes and two of blurred vision, and it was thought that the possibility of eye problems associated with nifedipine should be investigated. Disturbance of taste with captopril, a drug that was also being intensively monitored, is a known adverse reaction and was selected as a methodological control. Captopril was first marketed in","year":"1981","unstructured":"After the first two years ofmonitoring ofnifedipine five records of eye problems had been received, three of painful eyes and two of blurred vision, and it was thought that the possibility of eye problems associated with nifedipine should be investigated. Disturbance of taste with captopril, a drug that was also being intensively monitored, is a known adverse reaction and was selected as a methodological control. Captopril was first marketed in April 1981."},{"key":"ref_24","article-title":"Had treatment been stopped, and if so when?","volume-title":"Had their sense of taste changed and any eye problems developed since they started their treatment? (They were not told which drug was suspected of affecting the eyes or the sense of taste","year":"(2)","unstructured":"Had treatment been stopped, and if so when? (2) Had their sense of taste changed and any eye problems developed since they started their treatment? (They were not told which drug was suspected of affecting the eyes or the sense of taste.)"},{"key":"ref_25","article-title":"Iftheir sense oftaste had changed they were asked to choose the best answer for the change from sweet, loss of taste, salty, metallic, and other; and for eye problems they selected from painful, stinging or dry eyes, and blurred vision. Some ofthese choices were included as a blind","unstructured":"Iftheir sense oftaste had changed they were asked to choose the best answer for the change from sweet, loss of taste, salty, metallic, and other; and for eye problems they selected from painful, stinging or dry eyes, and blurred vision. Some ofthese choices were included as a blind."},{"key":"ref_26","article-title":"Had any of these symptoms caused them to stop taking the drug? (5) Had these symptoms cleared on withdrawal of the drug? (6) If symptoms were current they were asked to grade the severity in one of three categories: severe, moderate, or minor","unstructured":"Had any of these symptoms caused them to stop taking the drug? (5) Had these symptoms cleared on withdrawal of the drug? (6) If symptoms were current they were asked to grade the severity in one of three categories: severe, moderate, or minor."},{"key":"ref_27","article-title":"Did they smoke tobacco? Smoking could relate to taste and possibly eye problems","unstructured":"Did they smoke tobacco? Smoking could relate to taste and possibly eye problems."},{"key":"ref_28","article-title":"Date of birth","unstructured":"Date of birth."}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.296.6629.1083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T22:51:57Z","timestamp":1601074317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.296.6629.1083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1988,4,16]]},"references-count":28,"journal-issue":{"issue":"6629","published-print":{"date-parts":[[1988,4,16]]}},"URL":"https:\/\/doi.org\/10.1136\/bmj.296.6629.1083","relation":{},"ISSN":["0959-8138","1468-5833"],"issn-type":[{"value":"0959-8138","type":"print"},{"value":"1468-5833","type":"electronic"}],"subject":[],"published":{"date-parts":[[1988,4,16]]}}}